MedPageToday -- SAN FRANCISCO -- Two-thirds of patients with advanced gastrointestinal stromal tumors (GIST) achieved disease control after second- and third-line treatment with sorafenib (Nexavar), results of a small clinical trial showed. Five of 38 patients had partial responses, and 21 others had stable disease. Median progression-free survival (PFS) was 5.2 months and overall survival was 11.6 months, according to a study that will be presented here at the Gastrointestinal Cancers Symposium.
